Elevated glycosylation of CD36 in platelets is a risk factor for oxLDL-mediated platelet activation in type 2 diabetes.
CD36
T2D patients
glycosylation
oxLDL
platelet glycoproteins
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
16 Oct 2023
16 Oct 2023
Historique:
revised:
19
08
2023
received:
27
06
2023
accepted:
12
10
2023
pubmed:
17
10
2023
medline:
17
10
2023
entrez:
16
10
2023
Statut:
aheadofprint
Résumé
Platelet activation and related cardiovascular complications are the hallmarks of type 2 diabetes (T2D). We investigated the mechanism of platelet activation in T2D using MS-based identification of differentially expressed platelet proteins with a focus on glycosylated forms. Glycosylation is considered one of the common post-translational modifications in T2D, and N/O-linked glycosylation of glycoproteins (GPs)/integrins is known to play crucial roles in platelet activation. Our platelet proteome data revealed elevated levels of GPs GPIbα, GPIIbIIIa, GPIV (CD36), GPV and integrins in T2D patients. T2D platelets had elevated N-linked glycosylation of CD36 at asparagine (Asn)
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Biotechnology, Ministry of Science and Technology, India
ID : BT/PR22881
Organisme : Department of Biotechnology, Ministry of Science and Technology, India
ID : BT/PR22985
Organisme : Science and Engineering Research Board
ID : CRG/000092
Informations de copyright
© 2023 Federation of European Biochemical Societies.
Références
WHO report. https://www.who.int/news-room/fact-sheets/detail/diabetes
Martín-Timón I (2014) Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes 5, 444-470.
Ferroni P, Basili S, Falco A & Davì G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2, 1282-1291.
Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H & Gries FA (1990) Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 20, 166-170.
Welsh KJ, Kirkman MS & Sacks DB (2016) Role of glycated proteins in the diagnosis and management of diabetes: research gaps and future directions. Diabetes Care 39, 1299-1306.
Winocour PD, Watala C & Kinglough-Rathbone RL (1992) Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes from diabetic and control subjects. Thromb Haemost 67, 567-571.
Ramírez-López A, Román MTÁ, Manzano EM, Acuña P, Arias-Salgado EG, Martín Salces M, Rivas Pollmar MI, Jiménez Yuste V, Justo Sanz R, García Barcenilla S et al. (2010) The importance of platelet glycoside residues in the haemostasis of patients with immune thrombocytopaenia. J Clin Med 10, 1661.
Wang Y, Jobe SM, Ding X, Choo H, Archer DR, Mi R, Ju T & Cummings RD (2012) Platelet biogenesis and functions require correct protein O-glycosylation. Proc Natl Acad Sci U S A 109, 16143-16148.
Mammadova-Bach E, Jaeken J, Gudermann T & Braun A (2020) Platelets and defective n-glycosylation. Int J Mol Sci 21, 1-16.
Felber JP, Magnenat G, Casthelaz M, Geser CA, Muller-Hess R, de Kalbermatten N, Ebiner JR, Curchod B, Pittet P & Jéquier E (1977) Carbohydrate and lipid oxidation in normal and diabetic subjects. Diabetes 26, 693-699.
Geraldes P & King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106, 1319-1331.
Doens D, Valiente PA, Mfuh AM, X T Vo A, Tristan A, Carreño L, Quijada M, Nguyen VT, Perry G, Larionov OV et al. (2017) Identification of inhibitors of CD36-amyloid beta binding as potential agents for Alzheimer's disease. ACS Chem Nerosci 21, 1232-1241.
Hsieh J, Longuet C, Maida A, Bahrami J, Xu E, Baker CL, Brubaker PL, Drucker DJ & Adeli K (2009) Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 137, 997-1005.e4.
Magwenzi S, Woodward C, Wraith KS, Aburima A, Raslan Z, Jones H, McNeil C, Wheatcroft S, Yuldasheva N, Febbriao M et al. (2015) Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade. Blood 125, 2693-2703.
Nergiz-Unal R, Lamers MME, Van Kruchten R, Luiken JJ, Cosemans JMEM, Glatz JFC, Kuijpers MJ & Heemskerk JW (2011) Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein. J Thromb Haemost 9, 1835-1846.
Moog S, Mangin P, ge Lenain N, Strassel C, Ravanat C, Schuhler S, Freund M, Santer M, Kahn M, Nieswandt B et al. (2001) Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood 98, 1038-1046.
Silverstein RL (2009) Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress. Clin Lipidol 4, 767-779.
Shattil SJ (1999) Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost 82, 318-325.
Rudman N, Gornik O & Lauc G (2019) Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes. FEBS Lett 593, 1598-1615.
Toonstra C, Hu Y & Zhang H (2019) Deciphering the roles of N-glycans on collagen-platelet interactions. J Proteome Res 18, 2467-2477.
Ghoshal P, Rajendran M, Odo N & Ikuta T (2014) Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells. PLoS One 9, e99363.
Schulte Am Esch J, Robson SC, Knoefel WT, Hosch SB & Rogiers X (2005) O-linked glycosylation and functional incompatibility of porcine von Willebrand factor for human platelet GPIb receptors. Xenotransplantation 12, 30-37.
Ghosh A, Murugesan G, Chen K, Zhang L, Wang Q, Febbraio M, Anselmo RM, Marchant K, Barnard J & Silverstein RL (2011) Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood 117, 6355-6366.
Hoosdally SJ, Andress EJ, Wooding C, Martin CA & Linton KJ (2009) The human scavenger receptor CD36: glycosylation status and its role in trafficking and function. J Biol Chem 284, 16277-16288.
Holmes RS (2012) Comparative studies of vertebrate platelet glycoprotein 4 (CD36). Biomolecules 2, 389-414.
Goldberg IJ (2001) Clinical review 124: diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 86, 965-971.
Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan ALY, Fukami K, Thallas-Bonke V, Nawroth PP et al. (2009) Rage-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20, 742-752.
Kuda O, Pietka TA, Demianova Z, Kudova E, Cvacka J, Kopecky J & Abumrad NA (2013) Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164: SSO also inhibits oxidized low density lipoprotein uptake by macrophages. J Biol Chem 288, 15547-15555.
Coort SL, Willems J, Coumans WA, van der Vusse GJ, Bonen A, Glatz JF & Luiken JJ (2002) Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol Cell Biochem 239, 213-219.
Momken I, Chabowski A, Dirkx E, Nabben M, Jain SS, McFarlan JT, Glatz JF, Luiken JJ & Bonen A (2017) A new leptin-mediated mechanism for stimulating fatty acid oxidation: a pivotal role for sarcolemmal FAT/CD36. Biochem J 474, 149-162.
Dhungana H, Huuskonen MT, Jaronen M, Lemarchant S, Ali H, Keksa-Goldsteine V, Goldsteins G, Kanninen KM, Koistinaho J & Malm T (2017) Sulfosuccinimidyl oleate sodium is neuroprotective and alleviates stroke-induced neuroinflammation. J Neuroinflammation 14, 237.
Shrimali NM, Agarwal S, Kaur S, Bhattacharya S, Bhattacharyya S, Prchal JT & Guchhait P (2021) α-Ketoglutarate inhibits thrombosis and inflammation by prolyl hydroxylase-2 mediated inactivation of phospho-Akt. EBioMedicine 73, 103672.
Singhal R, Annarapu GK, Pandey A, Chawla S, Ojha A, Gupta A, Cruz MA, Seth T & Guchhait P (2015) Hemoglobin interaction with GP1bα induces platelet activation and apoptosis: a novel mechanism associated with intravascular hemolysis. Haematologica 100, 1526-1533.
Annarapu GK, Singhal R, Peng Y & Guchhait P (2016) Inhibition of Hb binding to GP1bα abrogates Hb-mediated thrombus formation on immobilized VWF and collagen under physiological shear stress. PLoS One 11, e0154276.
Saha S, Verma R, Kumar C, Kumar B, Dey AK, Surjit M, Mylavarapu SVS & Maiti TK (2022) Proteomic analysis reveals USP7 as a novel regulator of palmitic acid-induced hepatocellular carcinoma cell death. Cell Death Dis 13, 563.
Hsieh FL, Turner L, Bolla JR, Robinson CV, Lavstsen T & Higgins MK (2016) The structural basis for CD36 binding by the malaria parasite. Nat Commun 7, 12837.
Kumari A, Mittal L, Srivastava M & Asthana S (2022) Binding mode characterization of 13b in the monomeric and dimeric states of SARS-CoV-2 main protease using molecular dynamics simulations. J Biomol Struct Dyn 40, 9287-9305.
Srivastava M, Mittal L, Kumari A & Asthana S (2021) Molecular dynamics simulations reveal the interaction fingerprint of remdesivir triphosphate pivotal in allosteric regulation of SARS-CoV-2 RdRp. Front Mol Biosci 8, 639614.
Srivastava M, Mittal L, Sarmadhikari D, Singh VK, Fais A, Kumar A & Asthana S (2023) Template entrance channel as possible allosteric inhibition and resistance site for quinolines tricyclic derivatives in RNA dependent RNA polymerase of bovine viral diarrhea virus. Pharmaceuticals (Basel) 16, 376.
Srivastava M, Mittal L, Kumari A, Agrahari AK, Singh M, Mathur R & Asthana S (2022) Characterizing (un)binding mechanism of USP7 inhibitors to unravel the cause of enhanced binding potencies at allosteric checkpoint. Protein Sci 9, e4398.
Kumari A, Mittal L, Srivastava M, Pathak DP & Asthana S (2023) Deciphering the structural determinants critical in attaining the FXR partial agonism. J Phys Chem B 127, 465-485.
Purushotham N, Singh M, Paramesha B, Kumar V, Wakode S, Banerjee SK, Poojary B & Asthana S (2022) Design and synthesis of amino acid derivatives of substituted benzimidazoles and pyrazoles as Sirt1 inhibitors. RSC Adv 12, 3809-3827.
Varma DA, Singh M, Wakode S, Dinesh NE, Vinaik S, Asthana S & Tiwari M (2023) Structure-based pharmacophore mapping and virtual screening of natural products to identify polypharmacological inhibitor against c-MET/EGFR/VEGFR-2. J Biomol Struct Dyn 41, 2956-2970.
Roos K, Wu C, Damm W, Reboul M, Stevenson JM, Lu C, Dahlgren MK, Mondal S, Chen W, Wang L et al. (2019) OPLS3e: extending force field coverage for drug-like small molecules. J Chem Theory Comput 15, 1863-1874.
Mittal L, Tonk RK, Awasthi A & Asthana S (2021) Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach. Arch Biochem Biophys 713, 109059.
Kumari A, Mittal L, Srivastava M, Pathak DP & Asthana S (2021) Conformational characterization of the Co-activator binding site revealed the mechanism to achieve the bioactive state of FXR. Front Mol Biosci 8, 658312.
Mittal L, Kumari A, Suri C, Bhattacharya S & Asthana S (2020) Insights into structural dynamics of allosteric binding sites in HCV RNA-dependent RNA polymerase. J Biomol Struct Dyn 38, 1612-1625.
Panwar S, Kumari A, Kumar H, Tiwari AK, Tripathi P & Asthana S (2022) Structure-based virtual screening, molecular dynamics simulation and in vitro evaluation to identify inhibitors against NAMPT. J Biomol Struct Dyn 40, 10332-10344.